1Friedrich M, Villena-Heinsen C, Axt-Fliedner R, et al. Analysis of 25-hydr- oxyvitamin D3-1alpha-hydroxylase in cervical tissue.Anticancer Res, 2002, 22(1): 183-186.
2Friedrich M, Raft L, Mitschele T, et al. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer.Recent Results Cancer Res, 2003, 164:239-246.
3Friedrich M, Meyberg R, Axt-Fliedner R, et al. Vitamin D receptor(VDR) expression is not a prognostic factor in cervical cancer.Anticancer Res, 2002, 22(1): 299-304.
4Negri E, La Vecchia C, Franceschi S, et al. Intake of selected micronutrients and the risk of endometrial carcinoma. Cancer, 1996, 77(5): 917-923.
5Yabushita H, Hirata M, Noguchi M, et al. Vitamin Dreceptor in endometrial carcinoma and the differentiation-inducing effect of 1,25-dihydroxyvitamin D3 on endometrial carcinoma cell lines. J Obstet Gynaecol Res,1996, 22(6): 529-539.
6Saunders DE, Christensen C, Wappler NL, et al. Additive inhibition of RL95-2 endometrial carcinoma cell growth by carboplatin and 1,25 dihydroxyvitamin D3. Gynecol Oncol, 1993, 51(2): 155-159.
7Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol, 1994, 23(6): 1133-1136.
8Villena-Heinsen C, Meyberg R, Axt-Fliedner R, et al. Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma. Anti-cancer Res, 2002, 22(4): 2261-2267.
9Saunders DE, Christensen C, Williams JR, et al. Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. Anticancer Drugs,1995, 6(4): 562-569.
10Li P, Li C, Zhao X, et al. p27^KIP1 stabilization and G1 arrest by 1,25-dihydroxyvitamin D (3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skpl -Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem, 2004, 279(24): 25260-25267.
